Early Detection and Diagnosis

You have full text access to this OnlineOpen article

Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence

  1. Martin Spahn1,
  2. Susanne Kneitz2,
  3. Claus-Jürgen Scholz2,
  4. Nico Stenger1,
  5. Thomas Rüdiger3,
  6. Philipp Ströbel4,
  7. Hubertus Riedmiller1,
  8. Burkhard Kneitz1,†,*

Article first published online: 7 JUL 2009

DOI: 10.1002/ijc.24715

Issue

International Journal of Cancer

International Journal of Cancer

Volume 127, Issue 2, pages 394–403, 15 July 2010

Additional Information

How to Cite

Spahn, M., Kneitz, S., Scholz, C.-J., Stenger, N., Rüdiger, T., Ströbel, P., Riedmiller, H. and Kneitz, B. (2010), Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. Int. J. Cancer, 127: 394–403. doi: 10.1002/ijc.24715

Author Information

  1. 1

    Department of Urology and Paediatric Urology, University Medical School, University of Würzburg, Würzburg, Germany

  2. 2

    Microarray Core Unit, IZKF (Interdisciplinary Center for Clinical Research), University of Würzburg, Würzburg, Germany

  3. 3

    Institute of Pathology, Community Hospital Karlsruhe, University Medical Center Mannheim, University of Heidelberg, Würzburg, Germany

  4. 4

    Institute of Pathology, University Medical Center Mannheim, University of Heidelberg, Würzburg, Germany

  1. †

    Fax: +49-931-201-32719

*Department of Urology and Paediatric Urology, University Medical School, University of Würzburg, Oberdürrbacher Str. 8, D-97080 Würzburg, Germany

Publication History

  1. Issue published online: 20 MAY 2010
  2. Article first published online: 7 JUL 2009
  3. Accepted manuscript online: 7 JUL 2009 12:00AM EST
  4. Manuscript Accepted: 9 JUN 2009
  5. Manuscript Received: 16 JAN 2009

Funded by

  • Interdisciplinary Center for Clinical Research (IZKF), University of Wuerzburg

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article with Supporting Information (HTML) Get PDF (435K)

Keywords:

  • microRNA;
  • high risk prostate carcinoma;
  • metastasis;
  • miR-221;
  • prognosis

Abstract

Emerging evidence shows that microRNAs (miR) are involved in the pathogenesis of a variety of cancers, including prostate carcinoma (PCa). Little information is available regarding miR expression levels in lymph node metastasis of prostate cancer or the potential of miRs as prognostic markers in this disease. Therefore, we analyzed the global expression of miRs in benign, hyperplastic prostate tissue (BPH), primary PCa of a high risk group of PCa patients, and corresponding metastatic tissues by microarray analysis. Consistent with the proposal that some miRs are oncomirs, we found aberrant expression of several miRs, including the downregulation of miR-221, in PCa metastasis. Downregulation of miR-221 was negatively correlated with the expression of the proto-oncogen c-kit in primary carcinoma. In a large study cohort, the prostate-specific oncomir miR-221 was progressively downregulated in aggressive forms of PCa. Downregulation of miR-221 was associated with clinicopathological parameters, including the Gleason score and the clinical recurrence during follow up. Kaplan–Meier estimates and Cox proportional hazard models showed that miR-221 downregulation was linked to tumor progression and recurrence in a high risk prostate cancer cohort. Our results showed that progressive miR-221 downregulation hallmarks metastasis and presents a novel prognostic marker in high risk PCa. This suggests that miR-221 has potential as a diagnostic marker and therapeutic target in PCa.

View Full Article with Supporting Information (HTML) Get PDF (435K)